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A B S T R A C T
To achieve GSH-responsive 5-Fluorouridine (5-FU) delivery, a novel family of nanogel drug
carriers has been successfully prepared. The new class of PAHy-based nanogels was pre-
pared by the crossing-link reaction of poly-α, β-polyasparthydrazide (PAHy) chains and 3,3′-
dithiodipropionic acid (DTDPA) consisting of a redox-responsive chain network.This particle
highlights recent efforts in introducing a disulfide bond to drug delivery nanogel by DTDPA,
and the increased release properties of complex nanogels produced excellent glutathione
(GSH)-sensitivity and significant anti-tumor therapeutic efficacy. The PAHy-based nanogels
were characterized by Fourier transform infrared spectroscopy (FT-IR), dynamic light scat-
tering (DLS) (nano-particle size ~200 nm), UV–vis spectrometry, X-ray diffraction (XRD) and
differential scanning calorimetric (DSC). PAHy-based nanogels are promising controlled-
release carriers for the tumor-targeting delivery of the anticancer agent 5-Fluorouridine.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Among the anticancer drugs, cytotoxic types have some issues
of their systemic biodistribution and the succedent side effects
induced by the drug encroaching into not only healthy but also
target cells. Furthermore, rapid clearance and the inadaptable
pharmacokinetics of the drugs lead to the administration of
high drug doses, and a strict timetable for the patient in order
to achieve the desired therapeutic effect [1,2]. Here 5-Fluorouracil
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(5-FU) is taken as the model drug. 5-FU is an antimetabolite
anticancer drug. It has activities against a broad spectrum of
solid tumors (of the liver, breast, ovary, brain, etc.). Due to its
pyrimidine analogue structure, 5-FU could be incorporated into
DNA and RNA thus interferes with nucleoside metabolism,
leading to cell cytotoxicity and inducing cell death at last. Over
the past 50 years, some disadvantages have troubled the clini-
cal applications of 5-FU, including the drug resistance and its
high rate of metabolism, thus continuous administrations of
high doses are greatly needed in the maintenance of a thera-
peutic concentration, which may induce severe toxic effects
(including myelosupression and gastrointestinal, hematologi-
cal, neural and dermatological adverse side effects) if
concentrations are above a certain limit [3–5].
A controlled 5-FU delivery system is designed to have good
physical stability, small size (allowing passive targeting), ability
to carry adequate dose of 5-FU at the target cell and pro-
longed exposure of the cells to 5-FU, thus reducing the
unwanted side effects.Theoretically, redox-responsive nanogel
delivery is a much better choice for 5-FU. Firstly, nanogel formed
by physically or chemically cross-linked networks was one of
the most promising drug delivery systems exploited nowa-
days for its hydrogel-like properties, nano-scaled size, good
mechanical stability, good biocompatibility, low cytotoxicity,
highly water-up taken interior network, a large specific surface
area, and high loading capacity of cargo materials [6,7]. Up until
now, despite the burgeoning nanogel and pharmaceutical
knowledge is still far from enough, the biggest impetus to bring-
ing new, biodegradable and sensitive carrier representatives are
greatly needed. Secondly, more and more attention has been
paid to redox-sensitive materials based on disulfide bonds over
the past years [8–12]. For example, glutathione (GSH) is a tri-
peptide that could reduce disulfide bonds for its ability
of serving electrons. The GSH concentration is highest in
tumor cells, higher in cytoplasm and low in the extracellular
environment [13–15]. Thus, the high concentration of the in-
tracellular GSH and the tumor-cellular GSH make redox-
responsive nano-carriers appealing candidates for tumor-
targeted drug release according to the rapid reduction of
disulfide bond and the oxidization of GSH into GS-SG. In this
case, nano-carriers could be designed with a disulfide bond as
across-linked part. There is, thus, a need for the develop-
ment of redox-responsive nanogel delivery systems for 5-FU
to improve its controlled-release properties in order to provide
a GSH-responsive delivery that will enhance its therapeutic
effects while reducing its side effects.
To achieve all the aims above, a novel type nanogel made
from polyasparthydrazide (PAHy) and 3, 3′-dithiodipropionic acid
(DTDPA) was initially designed for the redox-responsive de-
livery of 5-FU. PAHy is obtained by polymerization of
polysuccinimide (PSI) [7,16,17]. The biocompatibility of PAHy
has been proved by in vitro and in vivo studies carried out else-
where [16]. Moreover, considering that PAHy is a poly-functional
polymer with great chemical versatility, it is reasonable to
suppose that some hydrazine groups could be exploited for
chemical linkage with other molecules [18]. Disulfide cross-
linked networks have been completed by the use of disulfide-
containing cross-linker DTDPA during network formation.The
obtained PAHy-DTDPA nanogels have not only a poly amino
acid structure, but also a high drug loading of more than 20%,
multiple chemical functionalities, excellent GSH-responsive
release properties and a superior redox-responsibility, thus they
can be used to increase the therapeutic effects and reduce the
side effects of cytotoxic anticancer 5-FU as a potential tumor-
targeting delivery carriers.
2. Materials and methods
2.1. Materials
L-aspartic acid (Asp) (99.9%), hydrazine hydrate, phosphoric acid
(H3PO4), succinic anhydride, n-octyl alcohol, polysorbate80
(Tween80), sorbitan oleate80 (Span80), paraformaldehyde,
n-hexane were chemical grade and were supplied by Shan Dong
Yu Wang Reagent Company. 3,3′-Dithiodipropionic acid (99%)
was purchased from Aladdin Industrial Corporation (Shang-
hai, China). N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS) were
obtained from Medpep Co., Ltd. (Shanghai, China). Deionized
water in the experiment was obtained by a Milli-Q purifica-
tion system. 5-Fluorouridine (5-FU) (99%) was purchased from
Mei Lan Industrial (Shanghai) Co., Ltd. Dulbecco’s modified Eagle
medium (DMEM) was obtained from Lifei biotechnology Co.,
Ltd (Shanghai, China). Fetal bovine serum (FBS) and penicillin-
streptomycin were purchased from Jingyang Biomaterials
Co., Ltd (Tianjin, China). 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyltetrazolium bromide (MTT).
2.2. Synthesis of polysuccinimide (PSI) and
polyasparthydrazide (PAHy)
Polysuccinimide (PSI) was synthesized by thermal polycon-
densation of aspartic acid in presence of phosphoric acid (85%)
under vacuum [16] in an oil bath at 180 °C.Then DMFwas added
to the brown viscousmatter and kept at room temperature over-
night.The white precipitate appeared in a large amount of cold
distilled water with intensive stirring and then be filtered and
washed several times to neutral with double distilled water.
At last the powder was dried at 70 °C for further use.
Polyasparthydrazide (PAHy) was prepared via PSI, which was
obtained by polycondensation of DL-aspartic acid (Asp) reacted
with hydrazine hydrate in DMF solution according to the pre-
vious reports with little modifications [17,19]. PAHy was isolated
by filtration, washed several times with acetone and then dried.
An aqueous solution of PAHy was dialyzed for 3 d against de-
ionized water using a dialysis membrane with a molecular
weight cutoff of 12,000–14,000 (MWCO 12 k–14 kDa). After di-
alysis, the PAHy was recovered by lyophilization with a yield
of 89.6% w/w based on the beginning PSI. Analytical data of
PAHy were in agreement with the reported values.
2.3. Preparation of PAHy-DTDPA series nanogels
A novel group of PAHy-DTDPA nanogels was prepared by using
PAHy and the cross-linker DTDPA with different crosslinking
densities. Firstly, DTDPA was activated by EDC and NHS. Sec-
ondly, PAHy was dissolved in adequate double distilled water.
Thirdly, both the solutions of PAHy and DTDPA were added
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dropwise into the mixture (n-hexane/n-octyl alcohol, 10:1, v/v,
Tween 80/Span 80, 3:1, w/w) under stirring in a water bathmain-
tained at 37 °C [20]. The obtained nanogels were purified by
several alternate washes with THF and double distilled water
then centrifuged at 12,000 rpm for 30 min after the solvents
were evaporated. Then the nanogels were recovered and dis-
persed in double distilled water (0.5 mg/ml) by Nanohomogenize
machine (Nano homogenize machine AH100D, ATS Engineer-
ing Inc.) at 400 bar, and stored at 4 °C [21]. The synthetic route
of PAHy-based nanogels and the chemical structures of DTDPA
and repeating units of PAHy was shown in Fig. 1.
2.4. Fourier Transform Infrared Spectroscopy (FT-IR) of
PAHy-based nanogels
In order to have more information about the formation of the
chemical linkages of nanogels, FourierTransform Infrared Spec-
troscopy (FT-IR, Bruker IFS 55, Switzerland) was carried out for
DTDPA, PAHy and the prepared nanogels. The FT-IR spectra of
the samples were measured in the range of 400–4000 cm−1 (KBr
discs).
2.5. Particle size measurements of the nanogels
The hydrodynamic diameters of the prepared redox-response
nanogels were measured by dynamic light scattering using a
Zeta-sizer Nano ZS90 (Malvern Instruments, Malvern, UK).The
measurements were repeated 3 times at 25 °C and the average
values were calculated.
2.6. Encapsulation of 5-FU
The anticancer drug 5-FU was chosen as a model drug to evalu-
ate the capability of loading of the nanogels.The 5-FU dispersion
was magnetically stirred in a water bath at 25 °C for several
minutes, then lyophilized PAHy-DTDPA nanogels (nanogels/
5-FU, 1:3, w/w) was added into the dispersion. The mixture
maintained ultrasonic state for 1 h and continuously stirred
Fig. 1 – The synthetic route of PAHy-based nanogels and chemical structures of DTDPA, repeating units of PAHy and
prepared nanogels.
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for another 3 d.Then the 5-FU loaded nanogels were removed
by successive centrifugation (12,000 rpm, 30 min) and decan-
tation [22,23]. The collected 5-FU-loaded nanogels were
obtained and the concentrations of the loaded amount of 5-FU
were determined by UV–vis spectrometry system (752N, Sunny
Hengping Scientific Instruments Co., Ltd, Shanghai) at λ ap-
proximately 270 nm.The drug loading (DL) and encapsulation
efficiency (EE) were calculated according to the following
formula:
DL
m
M
% %= ×1 100
EE
m
m
% %= ×1
0
100
Here, m0 is the mass of 5-FU added, m1 is the mass of 5-FU
encapsulated in nanogels, and M is the mass of 5-FU-loaded
nanogels.
2.7. X-ray diffraction (XRD) and differential scanning
calorimetric (DSC) analysis
The crystalline characteristics were carried out using X-ray
diffractometer (PW3040/60 PANALYII CALB.V Netherlands). XRD
patterns were obtained from the range of 5°~50° with a scan
rate of 5°/min and a step size of 0.02° [24].
DSC profiles were recorded on a DSC instrument (TA In-
struments, Q1000, USA).The samples of pure 5-FU, G1 and 5-FU
loaded G1were heated from 30 °C to 330 °C at a heating rate
of 10 °C/min in nitrogen atmosphere with the flow rate of
100 ml/min) [24].
2.8. In vitro drug release
The in vitro release properties of 5-FU-nanogel complexes were
evaluated in PBS solution at 100 rpm at 37 °C by dialysis method
[22,25] at different pH values containing different crosslinking
densities with or without GSH (Fig. 5). At predetermined
intervals (1, 2, 4, 7, 12 and 24 h), the released 5-FU in dialysis
medium were assayed at 270 nm with UV–vis spectrophotom-
eter. Each experiment was performed for three times. And
the standard errors of the cumulative release values were in
agreement within ±3%.
2.9. Tumor cells viability evaluations in vitro
B16F10 cells (7 × 103 cell/well) were cultured in Dulbecco’s modi-
fied Eagle medium (DMEM) containing 10% fetal bovine serum
(FBS) and 1% penicillin–streptomycin in a 96-well plate, and
then were exposed to various concentrations of free 5-FU so-
lutions, G1 nanogels or 5-FU-loaded G1 nanogel dispersion,
respectively [26,27]. The free 5-FU solutions, G1 nanogels and
5-FU loaded G1 nanogel dispersions (with equivalent 5-FU and
G1 nanogels concentrations) were prepared in PBS buffer and
added to the cell culture media, then the cells were incu-
bated for 24 h (37 °C, 5% CO2).The medium was then aspirated,
and the wells were washed three times using fresh serum-
free DMEM. After that, 50 μl of 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyltetrazolium bromide (MTT) solution (2.5 mg/ml PBS)
was added to the wells. After incubation for 4 h, the solution
was aspirated and 150 μl DMSO was added to each well to dis-
solve the formazan crystal. Then the plate was sealed and
incubated overnight at 37 °C with gentle mixing. Cell viabil-
ity (%) was determined using a microplate reader at 570 nm
by comparing with the control wells which contain only the
cell culture medium. Data are presented as average ± stan-
dard deviation (n = 5).
MCF-7 cells (1 × 104 cells per well) were cultured in DMEM
containing 10% FBS and 1% penicillin–streptomycin in a 96-
well plate at 37 °C with 5% CO2.Then they were exposed to the
various concentrations of free 5-FU, G1 nanogels and 5-FU-
loaded G1 nanogels, respectively. After 24 h of co-incubation,
the wells were rinsed three times with serum-free DMEM
to remove the nanogels that had not been internalized by
MCF-7 cells.The cell viability was finally assessed through MTT
assay as mentioned above (n = 5). Data are presented as
average ± standard deviation (n = 5).
2.10. Statistical analysis
Data were represented as mean ± SD of at least triple experi-
ments and all the calculations were performed using the SPSS®
statistical software program 17.0. The Mann–Whitney U-test
was utilized to survey statistical differences. In all circum-
stances, P < 0.05 was regarded as statistically significant.
3. Results and discussion
3.1. Synthesis and characterization of PAHy-DTDPA
nanogels
The cross-linking action was carried out by polymerization of
the hydrazine groups of PAHy and the dicarboxylic groups of
the cross-linker DTDPA. Specifically, the formation of a stable
network of nanogels was attributed to the substitution of the
NHS esters of DTDPA by hydrazine groups on PAHy. A series
of nanogels with different cross-linking densities (0.07, 0.14,
and 0.21) were prepared.The average hydrated particle size of
the dispersed nanogel (0.5 mg/ml) solution was approxi-
mately 200 nm. The nanogel hydrated diameters and the PDI
values varied within 5%, which confirmed the good stability
of all the prepared nanogels in dispersed solution.
As shown in the Table 1, with a growth in the CDs, the mean
sizes had a very little change. The CDs might be an essential
factor for the network structure, as tenser network holding less
water, and the particle size was smaller. It was assumed that
the size of nanogels was mainly determined by the initial char-
acteristics of the polymers. Moreover, droplets of the reverse
microemulsion played an important role for the nanogel for-
mation because the droplets work as a micro-reactor which
controls the final size and uniformity of the PAHy-DTDPA
nanogels. In the process of synthesis, the pH value had not been
adjusted because of the unstability of themicroemulsion system
after the addition of HCl solution. The droplet size of the
microemulsion could not be guaranteed in the range below
200 nm.And the nanogels were in the same situation.To make
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the experiment go on wheels, the reaction time and amounts
of EDC and NHS were both increased to make sure that the
reactions were complete (Fig. 1).
For the purpose of obtaining more information about the
formation of the network between PAHy and DTDPA, all the
prepared nanogels were measured by FT-IR spectroscopy. Fig. 2
showed the FT-IR spectra of PAHy-DTDPA nanogels in com-
parison with native PAHy and DTDPA. As shown in Fig. 2,
the FT-IR spectra of the G1 nanogel samples showed charac-
teristic peaks of PAHy and DTDPA such as —C=O, —CH2—,
—NH2— and —NH—. And there is an appearance of a peak of
—COO— in G1 nanogels FT-IR spectra. From these results, the
successful preparation of PAHy-based nanogels was inferred.
3.2. Encapsulation of 5-Fluorouridine (5-FU)
5-FU permeated into the network and dispersed uniformly with
the swelling of the nanogels.A dynamic equilibriumwas gradu-
ally formed. As shown in Table 1, the 5-FU-nanogels showed
a high EE% of approximately 90% and a high LD% approach-
ing nearly 20%, confirming the successfully loading of 5-FU. For
the reasons above, nanogels with stable network of poly-
amino acids containing disulfide bonds were successfully
prepared and used as a drug reservoir of 5-FU owing to their
high loading capability.
3.3. XRD and DSC analysis
The XRD patterns of free 5-FU, G1 nanogels and 5-FU loaded
G1 nanogels were shown in Fig. 3. The XRD patterns exhib-
ited sharp peaks in the 5-FU crystals. While the G1 nanogels
and 5-FU loaded G1 nanogels did not show any characteristic
5-FU diffraction peaks, suggesting that 5-FU was entrapped in
the nanogel network. Accordingly, it can be inferred that the
model drug (5-FU) had changed into a non-crystalline form and
at a homogeneous dispersion state in the network of the
nanogels [24,28–31].
The status of 5-FU loaded in the nanogels was further con-
firmed by DSC. Fig. 4 showed the DSC curves of pure 5-FU, G1
nanogel and 5-FU loaded G1 nanogel. 5-FU showed a sharp peak
at 285 °C, which was its melting point, while the G1 nanogels
and 5-FU loaded G1 nanogels showed no such peaks at the same
temperature, which suggested that 5-FU was dispersed in the
nanogel networks in a non-crystalline form [31,32]. These DSC
results all agreed with the XRD results.
Together, the XRD and DSC results confirmed the poten-
tial advantage of using PAHy-DTDPA nanogels as drug carriers.
Table 1 – Characterization, encapsulation efficiency (EE)
and loading drug capability (LD) of PAHy-DTDPA
nanogels (5-FU/nanogel, w/w 1:3).
Sample
code
Cross-
linker
Crosslinking
density
Mean
size
(nm)
PDI EE
(wt.%)
LD
(wt.%)
G1 DTDPA 0.07 184.8 0.231 92.09 23.14
G2 DTDPA 0.14 181.1 0.182 91.77 22.89
G3 DTDPA 0.28 176.7 0.205 90.83 22.15
Crosslinking density = moles of DTDPA/moles of PAHy repeating units,
where: The moles of EDC/ 2 × moles of DTDPA = 2, the moles of NHS/
moles of EDC = 1.
Fig. 2 – FT-IR spectra of native PAHy, DTDPA, PAHy-DTDPA nanogels (G1).
Fig. 3 – XRD analysis of pure 5-FU, G1 nanogels and 5-FU
loaded G1 nanogels.
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3.4. In vitro drug release
In this research, 5-FU-loaded PAHy-DTDPA nanogel systemwith
different crosslinking densities was prepared and the cumu-
lative 5-FU release in vitro was monitored for 24 h. In the
medium, the nanogels could hold the sustained release of some
of the loaded 5-FU as time goes by, until the nanogels reached
the tumor cells. Then the release of a large proportion of the
loaded 5-FU began to start by the trigger GSH.That is the idea
behind the design of PAHy-DTDPA redox-responsive nanogels.
Therefore, the release behaviors at various pH values, with dif-
ferent crosslinking densities, ionic strengths andwith or without
GSH, were all investigated using the crude 5-FU as a control
(Fig. 5).
In the prime of the release experiments, the release of
crude 5-FU from the nanogels was relatively rapid (almost
100.0%) into an aqueous environment and the sustained release
was obtained from G1 (51.2%), G2 (43.2%) and G3 (41.4%) as
shown in Fig. 5A. The release curves of crude 5-FU at pH 1.2,
6.5 and 7.4 (around 100%) were analogous but all more than
that from the nanogels (G1, 58.1% at pH 1.2; 55.2% at pH 6.5;
45.5% at pH 7.4) in Fig. 5B. As expected, the release behavior
of 5-FU relied on the presence of GSH (from 41.4% to 91.1% at
pH 6.5) (Fig. 5C). It was noticed that, as increasing of the
concentration of GSH, the disulfide bonds were cleaved and
the network of the nanogels was collapsed quickly thus the
release of 5-FU was effectively accelerated (Fig. 5D). The cu-
mulative release of 5-FU was 51.5% at 2 h and after 24 h it
even reached 91.1%.
To summarize, there was a burst release initially. After that,
slowly and gradually release occurred over a period of obser-
vation. The release process of the loaded 5-FU presented two
major phases: i) A burst release phase appeared at the first 2 h.
ii) Then a sustained release phase occurred and lasted to the
end. In the first 2 h, the occurrence of transient release was
Fig. 4 – DSC analysis of pure 5-FU, G1 nanogels and 5-FU
loaded G1 nanogels.
Fig. 5 – 5-FU cumulative release from nanogels. (A) Different CDs in pH 6.5; (B) 5-FU and 5-FU loaded G1, in PBS with
different pH values; (C) 5-FU loaded G1, presence of GSH or not, at pH 6.5; (D) 5-FU loaded G1, different concentrations of
GSH, at pH 6.5 (n = 3).
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because only a small proportion of 5-FU loaded into the outer
layer or on the surface of the nanogels began to diffuse into
the medium. Second release phase exhibited diffusion-
controlled behavior [7]. As was reported, the mesh size of
hydrogels was in the range of 5~100 nm (when they are at
swollen state), and was much smaller than most of the small
molecule drugs. Thus, the diffusion behavior of 5-FU from the
nanogels and the physical properties of the nanogel network
(mechanical strength, degradation, dispersion, etc.) weremajorly
determined by the mesh size.The affected parameters includ-
ing the crosslinking density as well as the type and intensity
of the external stimuli deserved further consideration, while
the pH values and the GSH were taken into account. As shown
in Fig. 5, the tested parameters affected the mesh size and the
release of 5-FU over the experiment period.The release medium
penetrated into the cores of the network gradually, and 5-FU
processed sustained release into the media through the mesh
network barrier via diffusion.The PAHy-DTDPA nanogels acted
as retardants when they contacted with the release medium
and prevented the diffusion of 5-FU molecules [33–36]. And the
5-FU loaded in the interior of the network could be another
influencing factor.The more imbibition of the media, the bigger
mesh size, the looser the network and the better the release
characteristics obtained by the designed nanogels. So G1
nanogels showed the highest release rate and the extent of the
cumulative release as well as that of crude 5-FU was much
lower. The cumulative release of 5-FU was less than 100% and
the release properties were associated with the network struc-
ture, as a small number of 5-FU may be absorbed inside the
network while the remaining 5-FU may be released after the
end of the experiment period. All these results suggested that
the network who acted as an obstacle could retain the loaded
5-FU in the network and prevent its undesired leaching from
the network in the absence of GSH, but the disulfide bond can
be cleaved when it was under exposure to a reduction envi-
ronment (GSH for example) to induce the release of the cargo
drug molecules. Accordingly, the nanogels control the release
of 5-FU powerfully which will maintain the sustained release
for 24 h.This finding clearly shows that the release of 5-FU from
PAHy-DTDPA nanogel delivery systems could be controlled and
had a superior redox-responsibility.
3.5. Tumor cells viability evaluations in vitro
To further evaluate the effects of 5-FU loaded nanogel deliv-
ery systems, in vitro tumor cell viability tests were elaborately
conducted against B16F10 cells and MCF-7 cells. B16F10 and
MCF-7 cells were treated with free 5-FU, G1 nanogels and 5-FU
loaded G1 nanogels respectively. It is noted that the treat-
ment with nanogels alone for 24 h showed no significant
cytotoxicity on cells. In contrast, the cell viability drastically
decreased when the cells were exposed to free 5-FU solution
and 5-FU-loaded nanogels, demonstrating their high toxicity.
It is indicated that 5-FU loaded G1 nanogels led to an overall
decrease of the cell viability (Figs. 6 and 7). The significantly
decrease viabilities of B16F10 and MCF-7 cells occurred from
93% to 41% and from 99% to 61%, respectively. The fact that
the cytotoxicity of 5-FU loaded G1 nanogels was higher than
that of nanogels at all the studied concentrations was reason-
able due to the release of the loaded 5-FU from G1 nanogels
(Figs. 6 and 7). The lower cytotoxicity of the 5-FU loaded G1
nanogels than free 5-FU solutions might be attributed to the
sustained release property of the 5-FU-loaded G1 nanogels and
5-FU has a high inhibitory effect on cell growth [26,37].
These results indicated that the nanogels were nontoxic and
showed very high cell viability and the 5-FU loaded nanogels
provide high anti-cancer activity attributing to their con-
trolled release.
4. Conclusions
PAHy-DTDPA nanogels with disulfide bond made from
polyasparthydrazide (PAHy) and 3, 3′-dithiodipropionic acid
(DTDPA) and initially designed for the delivery of 5-Fluorouridine
(5-FU), have been successfully prepared. We confirmed their
biocompatible poly (amino acid) structure, high drug loading
capability, sustained release properties and superior redox-
responsibility and improved anti-tumor therapeutic efficacy.
Fig. 6 – The viability of B16F10 cells after treatments with
free 5-FU solutions, G1 nanogels and 5-FU loaded G1
nanogels dispersion for 24 h.
Fig. 7 – The viability of MCF-7 cells after treatments with
free 5-FU solutions, G1 nanogels and 5-FU loaded G1
nanogels dispersion for 24 h.
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Overall, these PAHy-based nanogels will be excellent as car-
riers of anti-cancer drug (5-FU).
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